Background
Echocardiographically detected patent foramen ovale (PFO) has been associated with stroke/transient ischemic attack (TIA) in patients with cardiac implantable electronic devices (CIED). We sought to evaluate the relationship between echocardiographic characteristics and risk of stroke/TIA and mortality in CIED patients with PFO.
Methods
In 6086 device patients, PFO was detected in 319 patients. A baseline echocardiogram was present in 250 patients, with 186 having a follow-up echocardiogram.
Results
Out of 250 patients with a baseline echocardiogram, 9.6% (n=24) had a stroke/TIA during mean follow-up of 5.3 ± 3.1 years; and 42% (n=105) died over 7.1 ± 3.7 years. Atrial septal aneurysm (ASA), prominent Eustachian valve (EV), visible shunting across PFO, baseline or change in estimated right ventricular systolic pressure (RVSP)/tricuspid regurgitation (TR) or maximum RVSP were not associated with post-implant stroke/TIA (p>0.05). An exploratory multivariate analysis using time-dependent cox models showed increased hazard of death in patients with increase in TR ≥2 grades (HR 1.780, 95% CI 1.447 – 2.189, p<0.0001) or increase in RVSP by >10 mmHg (HR 2.018, 95% CI 1.593 – 2.556, p<0.0001) or maximum RVSP in follow up (HR 1.432, 95% CI 1.351 – 1.516, p<0.0001). A significant increase (p-value <0.001) in TR was also noted during follow up.
Conclusions
In patients with CIED and PFO, structural and hemodynamic echocardiographic markers did not predict future stroke/TIA. However, a significantly higher TR or RVSP was associated with higher mortality.